IBT
XENT

International Biotechnology Trust’s Intersect ENT, Inc XENT Stock Holding History

International Biotechnology Trust’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-96,000
Closed -$2.18M – 65
2019
Q2 		$2.18M Hold
96,000
– – 0.81% 31
2019
Q1 		$3.09M Hold
96,000
– – 1.14% 31
2018
Q4 		$2.12M Sell
96,000
-16,000
-14% -$469K 1.32% 23
2018
Q3 		$2.47M Hold
112,000
– – 1.17% 28
2018
Q2 		$4.19M Buy
112,000
+75,000
+203% +$2.94M 1.61% 22
2018
Q1 		$1.45M Buy
+37,000
New +$1.35M 0.57% 39

Other funds holding XENT

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

International Biotechnology Trust's XENT Position: Q3 2019 in Review

International Biotechnology Trust sold out of Intersect ENT, Inc (XENT) in Q3 2019, closing a stake of 96,000 shares — an estimated $2.18M sold.

International Biotechnology Trust first reported a position in XENT in Q1 2018 and held it in 6 quarters. The position peaked at $4.19M in Q2 2018. 112 funds tracked by Wall St. Rank hold XENT as of Q3 2019.

  • International Biotechnology Trust reported no remaining Intersect ENT, Inc position as of Q3 2019 after selling out during the quarter.
  • International Biotechnology Trust sold 96,000 Intersect ENT, Inc shares in Q3 2019, an estimated $2.18M.
  • International Biotechnology Trust first reported a position in Intersect ENT, Inc in Q1 2018 and held it in 6 quarters.
  • International Biotechnology Trust's Intersect ENT, Inc position peaked at $4.19M in Q2 2018.
  • 112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2019.

Based on International Biotechnology Trust's 13F filing for Q3 2019, filed 14 Nov 2019.